Abstracts Archive - Page 1815 of 2607 - ACR Meeting Abstracts

Abstract Number: 3245 • 2016 ACR/ARHP Annual Meeting
Surfactant Protein D and Krebs Von Den Lungen-6 Predict Severity of Systemic Sclerosis-Related Interstitial Lung Disease in Two Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin², Faye N. Hant³, Galina S. Bogatkevich⁴, Michael Roth⁵, Kim Hyun⁶, Jonathan Goldin¹, Tanjina Akter⁷, Holly Wilhalme¹, Chi-hong Tseng⁵, Shervin Assassi⁸, Dinesh Khanna⁹, Philip J. Clements⁵, Daniel E. Furst¹, Robert Elashoff¹⁰ and Richard Silver¹¹, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Radiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷Department of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Biomathematics, University of California, Los Angeles, Los Angeles, CA, ¹¹Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC
Background/Purpose: A prior study of patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) demonstrated that serum concentrations of surfactant protein D (SP-D) and Krebs von…
Abstract Number: 3246 • 2016 ACR/ARHP Annual Meeting
Predictors of Long-Term Outcomes in Systemic Sclerosis Associated Pulmonary Arterial Hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry
Kathleen Kolstad¹, Shufeng Li², Virginia D. Steen³ and Lorinda Chung⁴, ¹Rheumatology, Stanford Univeristy, Stanford, CA, ²Dermatology, Stanford University, Stanford, CA, ³Rheumatology, Georgetown University Medical Center, Washington, DC, ⁴Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc). Predictors of short-term mortality include male sex, age>60…
Abstract Number: 3247 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Belimumab with Background Mycophenolate for Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Placebo Controlled, Pilot Trial
Jessica K. Gordon¹, Eliza Pelrine², Yuo-Yu Lee³, Cynthia Magro⁴, Elana J. Bernstein⁵, Horatio F. Wildman⁶ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Pathology, Weill Cornell Medical College, New York, NY, ⁵Department of Medicine, Division of Rheumatology, Columbia University, New York, NY, ⁶Dermatology, Weill Cornell Medical College, New York, NY
Background/Purpose: Abnormalities of B cell function are part of the pathogenesis of systemic sclerosis (SSc), and B-lymphocyte stimulator (BLyS) is increased in the serum and…
Abstract Number: 3248 • 2016 ACR/ARHP Annual Meeting
Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post-Hoc Analyses from the Scleroderma Lung Study I and II
Rajaie Namas^1,2, Donald P. Tashkin³, Holly Wilhalme⁴, Daniel E. Furst⁵, Chi-hong Tseng⁶, Michael Roth⁶, Suzanne Kafaja⁷, Elizabeth R. Volkmann⁴, Philip J. Clements⁶ and Dinesh Khanna⁸, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ³David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁴University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵UCLA, Los Angeles, CA, ⁶Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸University of Michigan, Ann Arbor, MI
Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post-hoc analyses from the Scleroderma Lung Study I and II. Background/Purpose: Assess the efficacy of…
Abstract Number: 3249 • 2016 ACR/ARHP Annual Meeting
Improvement in Cough and Cough-Related Quality of Life in Participants Undergoing Treatment for Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Dinesh Khanna², Chi-hong Tseng³, Robert Elashoff⁴, Bingling Wang⁵, Michael Roth³, Philip J. Clements³, Daniel E. Furst¹, Arthur Theodore⁶ and Donald P. Tashkin⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁵Biostatistics, University of California, Los Angeles, Los Angeles, CA, ⁶Medicine, Boston University, Boston, MA, ⁷David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: While chronic cough occurs in the majority of patients with systemic sclerosis-related interstitial lung disease (SSc-ILD),1 its impact on quality of life has not…
Abstract Number: 3250 • 2016 ACR/ARHP Annual Meeting
Serum MCP-1 Levels Predict Long-Term Progression of Interstitial Lung Disease in Systemic Sclerosis
Minghua Wu¹, Murray Baron², Marie Hudson³, Marvin J. Fritzler⁴, Claudia Pedroza⁵, Jun Ying¹, Gloria Salazar¹, Julio Charles⁶, Maureen D Mayes¹ and Shervin Assassi¹, ¹Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ²Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ³Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁵Pediatrics, University of Texas-McGovern Medical School, Houston, TX, ⁶Internal Medicine-Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Currently available clinical biomarkers are not reliable predictors of long-term progression of interstitial lung disease (ILD) in the context of systemic sclerosis (SSc) A previous…
Abstract Number: 3251 • 2016 ACR/ARHP Annual Meeting
Sleep and Physical Activity: A Nationwide Survey Among People with Rheumatic Disease in Ireland
Sean McKenna¹, Alan Donnelly², Sandy Fraser³ and Norelee Kennedy¹, ¹Department of Clinical Therapies, University of Limerick, Ireland, Limerick, Ireland, ²Department of Physical Education and Sports Sciences, University of Limerick, Ireland, Limerick, Ireland, ³Department of Rheumatology, University Hospitals Limerick, Ireland, Limerick, Ireland
Background/Purpose: Sleep is an important aspect in maintaining the body’s circadian rhythm and plays an important role in maintaining health. Disrupted or lower levels…
Abstract Number: 3252 • 2016 ACR/ARHP Annual Meeting
Content Analysis of Ergonomic Recommendations Using the Ergonomic Assessment Tool for Arthritis
Lisa Allyn¹, Lisa Zoller¹, Catherine L. Backman^2,3 and Diane Lacaille^4,5, ¹The University of British Columbia, Vancouver, BC, Canada, ²Department of Occupational Science & Occupational Therapy, The University of British Columbia, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, ⁴Medicine, University of British Columbia, Vancouver, BC, Canada, ⁵Arthritis Research Canada, Richmond, BC, Canada
Background/Purpose: Work cessation and at-work productivity loss are common and early outcomes of inflammatory arthritis (IA). Ergonomic accommodations contribute to successful management of arthritis symptoms…
Abstract Number: 3253 • 2016 ACR/ARHP Annual Meeting
Minimum Physical Function Needed to Walk 6000 Steps/Day in People with Knee Osteoarthritis
Hiral Master¹, Louise Thoma¹, Meredith Christiansen¹, Emily Polakowski¹, Laura Schmitt¹ and Daniel White², ¹Physical Therapy and Biomechanics and Movement Science, University of Delaware, Newark, DE, ²Department of Physical Therapy, University of Delaware, Newark, DE
Title: Minimum Physical Function Needed To Walk 6000 steps/day In People With Knee Osteoarthritis. Background/Purpose: Adopting a physically active lifestyle provides major health benefits to…
Abstract Number: 3254 • 2016 ACR/ARHP Annual Meeting
Use of the Short Valued Life Activities Scale in People with Systemic Sclerosis
Janet L. Poole¹ and Betty Skipper^2,3, ¹Health Sciences Ctr OT Program, 1 University of New Mexico, Albuquerque, NM, ²Family and Community Medicine, University of New Mexico, Albuquerque, NM, ³Family and Community Medicine, University of New Mexico, University of New Mexico, Albuquerque, NM
Background/Purpose: Systemic sclerosis is a chronic autoimmune connective tissue disorder that results in skin thickening, vascular insufficiency, and fibrosis of internal organs, such as…
Abstract Number: 3255 • 2016 ACR/ARHP Annual Meeting
A Randomized Trial of Automated Telephone-Linked Communication to Improve Exercise Adherence for a Progressive Resistance Training Program in People with Knee Osteoarthritis
Kristin Baker¹, Aileen Ledingham¹, Carrie Brown², Kelly Pesanelli³, Faye Cochrane⁴, Robert Friedman⁵, Michael P. LaValley⁶, David T. Felson⁷ and Julie J. Keysor^1,8, ¹Physical Therapy, Boston University Sargent College, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Health Sciences, Boston University Sargent College, Boston, MA, ⁴ENACT, Boston University Sargent College, Boston, MA, ⁵Boston University School of Medicine, Boston, MA, ⁶Biostatistics, Boston University School of Public Health, Boston, MA, ⁷Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁸Clinical Epidemiology Research and Training, Boston University School of Medicine, Boston, MA
Background/Purpose: In knee osteoarthritis (OA) strengthening exercise improves pain and physical function, however a marked decline in exercise adherence has limited the long term efficacy…
Abstract Number: 3256 • 2016 ACR/ARHP Annual Meeting
Functional Ability ‘to Rise’ and Autonomy Support for Physical Activity: Implications for Light Physical Activity Engagement and Psychological Wellbeing in People Living with Rheumatoid Arthritis
Sally Fenton^1,2, Jet Veldhuijzen van Zanten², George Metsios^2,3, Peter Rouse⁴, Chen-an Yu⁵, George D. Kitas^1,2 and Joan Duda¹, ¹School of Sport, Exercise and Rehabilitation, University of Birmingham, Birmingham, United Kingdom, ²Department of Rheumatology, Russells Hall Hospital, Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom, ³Department of Physical Activity Exercise and Health, University of Wolverhampton, Walsall, United Kingdom, ⁴Department for Health, University of Bath, Bath, United Kingdom, ⁵School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Epidemiological studies indicate participation in light physical activity (LPA) is positively associated with psychological wellbeing. For patients with Rheumatoid Arthritis (RA), reduced functional ability…
Abstract Number: 1L • 2015 ACR/ARHP Annual Meeting
Tocilizumab for the Treatment of Giant Cell Arteritis – a Randomized Placebo-Controlled Trial
Sabine Adler¹, Stephan Reichenbach², Stefan Kuchen³, Felix Wermelinger², Diana Dan², Peter M. Villiger² and Michael Seitz², ¹Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ²Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland, ³Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, MD, Switzerland
Background/Purpose: Giant cell arteritis (GCA) is characterized by a destructive, granulomatous inflammation in the walls of medium and large-sized arteries. Glucocorticoid (GC) treatment controls symptoms…
Abstract Number: 2L • 2015 ACR/ARHP Annual Meeting
Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study
Peter C. Taylor¹, Edward C. Keystone^2,3, D. van der Heijde⁴, Yoshiya Tanaka⁵, Taeko Ishii⁶, Kahaku Emoto⁶, Lili Yang⁶, Vipin Arora⁶, Carol L. Gaich⁶, Terence Rooney⁶, Douglas E. Schlichting⁶, William Macias⁶, Stephanie de Bono⁶ and Michael E. Weinblatt⁷, ¹Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom, ²University of Toronto, Toronto, ON, Canada, ³Rebecca MacDonald Centre, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵The First Dept. of Internal Medicine, University of Occupational & Environmental Health, Kitakyusyu, Japan, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Brigham and Women’s Hospital, Boston, MA
Background/Purpose: In phase 3 studies, baricitinib (bari) improved disease activity in patients (pts) with active RA and an inadequate response (IR) to conventional synthetic DMARDs1…
Abstract Number: 3L • 2015 ACR/ARHP Annual Meeting
A Randomised Controlled Trial of the Clinical Effectiveness, Safety and Cost-Effectiveness of Adalimumab in Combination with Methotrexate for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis
Athimalaipet V Ramanan¹, Andrew D. Dick², Andrew McKay³, Ashley Jones⁴, Paula Williamson⁴, Sandrine Compeyrot-Lacassagne⁵, Ben Hardwick⁴, Helen Hickey⁴, Dyfrig Hughes⁶, Patricia Woo⁵, Diana Benton¹, Clive Edelsten⁵ and Michael W. Beresford⁷, ¹University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom, ²University of Bristol, Bristol Eye Hospital, Bristol, United Kingdom, ³Biostatistics, Clinical Trials Research Centre, University of Liverpool, Liverpool, United Kingdom, ⁴Clinical Trials Research Centre, University of Liverpool, Liverpool, United Kingdom, ⁵Great Ormond Street Hospital, London, United Kingdom, ⁶Bangor University, Bangor, United Kingdom, ⁷University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Uveitis associated with Juvenile Idiopathic Arthritis (JIA) is a major cause of morbidity with potentially sight-threatening complications. Despite current screening and (pre-biologic) therapeutic options,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].